394 related articles for article (PubMed ID: 7738712)
1. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
[TBL] [Abstract][Full Text] [Related]
2. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
3. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7.
Symmans PJ; Linehan JM; Brito MJ; Filipe MI
J Pathol; 1994 Jul; 173(3):221-6. PubMed ID: 7931842
[TBL] [Abstract][Full Text] [Related]
4. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
5. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
6. Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53.
Iannettoni MD; Lee SS; Bonnell MR; Sell TL; Whyte RI; Orringer MB; Beer DG
Ann Thorac Surg; 1996 Nov; 62(5):1460-5; discussion 1465-6. PubMed ID: 8893584
[TBL] [Abstract][Full Text] [Related]
7. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
[TBL] [Abstract][Full Text] [Related]
8. Detection of p53 nuclear protein accumulation in brushings and biopsies of Barrett's esophagus.
Tsai TT; Bongiorno PF; Orringer MB; Beer DG
Cancer Detect Prev; 1997; 21(4):326-31. PubMed ID: 9232323
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
Klump B; Hsieh CJ; Holzmann K; Borchard F; Gaco V; Greschniok A; Eckardt VF; Bettendorf U; Gregor M; Porschen R
Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
11. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours.
Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
Eur J Surg Oncol; 2007 Dec; 33(10):1164-8. PubMed ID: 17467227
[TBL] [Abstract][Full Text] [Related]
12. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
[TBL] [Abstract][Full Text] [Related]
13. p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele.
Chung SM; Kao J; Hyjek E; Chen YT
Int J Oncol; 2007 Dec; 31(6):1351-5. PubMed ID: 17982662
[TBL] [Abstract][Full Text] [Related]
14. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
[TBL] [Abstract][Full Text] [Related]
16. [Overexpression of protein p53 and Barrett esophagus. A frequent and early event in the course of carcinogenesis].
Fléjou JF; Volant A; Diebold MD; Sagan C; Vissuzaine C; Croué A; Robaszkiewicz M; Potet F
Gastroenterol Clin Biol; 1995 May; 19(5):475-81. PubMed ID: 7589998
[TBL] [Abstract][Full Text] [Related]
17. MUC4 is increased in high grade intraepithelial neoplasia in Barrett's oesophagus and is associated with a proapoptotic Bax to Bcl-2 ratio.
Bax DA; Haringsma J; Einerhand AW; van Dekken H; Blok P; Siersema PD; Kuipers EJ; Kusters JG
J Clin Pathol; 2004 Dec; 57(12):1267-72. PubMed ID: 15563666
[TBL] [Abstract][Full Text] [Related]
18. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
19. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
[TBL] [Abstract][Full Text] [Related]
20. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
